Synopsis:
A small-cap company’s shares are in focus after the company announced the record date for the issue of bonus shares in the ratio 2:1.
A small-cap company that is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India, gained attention after announcing the record date for issue of bonus shares in the ratio of 2:1.
With Market Capitalization of Rs. 8,329.46 crore, Thyrocare Technologies Ltd is trading at 1,569.30, up by 0.34 percent from its previous closing price of Rs. 1,564 per equity share. The stock has touched an intraday high of Rs. 1,608.90 in today’s trading session, implying upside of 2.87 percent from previous day’s close price.
What’s the News?
Thyrocare Technologies Limited has announced a record date for the 2:1 bonus share issue, giving two new fully paid-up equity shares of Rs. 10 for each existing share. The company has fixed Friday, November 28, 2025, as the record date to determine shareholder eligibility for the bonus shares.
The deemed date of allotment of the bonus shares is Monday, December 1, 2025, and the shares will be available for trading from the next working day, Tuesday, December 2, 2025.
A bonus issue is a practice where a company distributes additional shares to existing shareholders for free, according to a set ratio, using its earnings. Here, the company has opted to issue bonus shares instead of distributing profits as dividends.
About the Company
Thyrocare Technologies Limited, founded in 1996 and headquartered in Navi Mumbai, is a diagnostic service provider operating through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company offers a wide range of pathological and diagnostic tests, sells consumables used in sample collection and pathology promotion, provides radio-pharmaceuticals and imaging consumables, and markets testing equipment along with its sugarscan glucometers and strips. Serving patients, hospitals, and laboratories across India, Thyrocare functions as a subsidiary of Docon Technologies Private Limited.
It is trading at a price-to-earnings (P/E) ratio of 65.2x, which is higher than the industry average of 42x. A return on equity (ROE) of about 16.2 percent and a return on capital employed (ROCE) of about 24.8 percent and debt to equity at 0.05 demonstrate the company’s financial position.
The company posted revenue of Rs. 217 crore in Q2FY26, up 22.5 percent YoY from Rs. 177 crore and 12.4 percent QoQ from Rs. 193 crore, reflecting strong growth momentum. Profit rose to Rs. 48 crore, increasing 26.3 percent YoY from Rs. 38 crore and 84.6 percent QoQ from Rs. 26 crore, indicating robust improvement in margins.
Written By Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
